New York, July 9th, 2020 - Creative Bioarray, the world’s leading biotechnology products and services provider, recently announced its implementation on the histology services with more comprehensive services including immunohistochemistry (IHC), immunofluorescence (IF), in situ hybridization (ISH), fluorescent in situ hybridization (FISH), and transmission electron microscopy.
Creative Bioarray has already confirmed the capability to produce high-quality and reproducible IHC stained slides with unparalleled efficiency. The entire IHC team has been fully trained to operate and maintain the machine and is ready to put the system to good use. The strategy and experimental design offered by Creative Bioarray will best fit specific needs and herein to accelerate the speed of research goals. Meanwhile, the customized service that will dramatically reduce operating costs by eliminating the complicated time-consuming processes of ISH also is available. The routine and custom ISH services are flexible to meets the needs ranging from tissue sections preparation to probe design, labeling and purification, as well as further hybridization and ISH staining.
Drawing on many years of experience and in-depth knowledge, Creative Bioarray can fully understand the advantages and pitfalls of fluorescence in situ hybridization (FISH), therefore offering fluorescence in situ hybridization (FISH) service range from standardized testing of validated assays to custom development of new assays. With excellent in-house scientists and experts who have years of experience in histology and FISH, Creative Bioarray can guarantee the speed, quality and cost of FISH service.
M-FISH is a general-purpose tool for precise chromosome separation and rapid chromosome classification, helping to speed up the workflow. Complementing standard cytogenetic methods, it helps to decipher complex chromosomal rearrangements and is used to identify non-random structural chromosomal rearrangements that other methods cannot detect. M-FISH characterizes genomic changes in many tumor cell lines. M-FISH offered in Creative Bioarray has unparalleled advantages: such as rapid analysis of mid-term diffusion, and the ability to analyze complex cases with multiple chromosome rearrangements and identify marker chromosomes, to distinguish between different imbalances that can be detected in aCGH, and it can also accurately karyotype a single midterm without selection.
“Our company is committed to providing consistent, high-quality histology services with quick turn-around times to the international scientific research community.” said Hannah Cole, the marketing director of Creative Bioarray, she also added, “whether it is a pilot project requiring custom protocol development or a large-scale multi-timepoint drug efficacy study, each project is individually customized and undergoes the strictest of quality control measures before being presented back to our valuable client.”
About Creative Bioarray
Creative Bioarray is a global drug discovery and development service company providing professional platforms to advance oncology, drug development, and many other disease research. With an extensive portfolio of relevant research models and predictive tools, Creative Bioarray enables itself to work with clients within the Drug Development, Medical Device, Pharmaceutical, Government, and Academic sectors.
For more information, visit https://www.creative-bioarray.com/.